ArticlePharmaceutical research1999
In vitro evaluation of microparticles and polymer gels for use as nasal platforms for protein delivery.
Article in Pharmaceutical research, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 139 citations in OpenAlex.
- Computational,Biomedicines · 2023Review
- Chitosan Aerogel Particles as Nasal Drug Delivery Systems.Gels (Basel, Switzerland) · 2022Article
- PA-X protein of H1N1 subtype influenza virus disables the nasal mucosal dendritic cells for strengthening virulence.Virulence · 2022Article
- Intranasal delivery of paeoniflorin nanocrystals for brain targeting.Asian journal of pharmaceutical sciences · 2020Article
- Use of Biopolymers in Mucosally-Administered Vaccinations for Respiratory Disease.Materials (Basel, Switzerland) · 2019Review
- Mucus models to evaluate the diffusion of drugs and particles.Advanced drug delivery reviews · 2018Review
- CpG Oligodeoxynucleotides Facilitate Delivery of Whole Inactivated H9N2 Influenza Virus via Transepithelial Dendrites of Dendritic Cells in Nasal Mucosa.Journal of virology · 2015Article
- H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice.Clinical and vaccine immunology : CVI · 2015Article
- Enhancement of nasal HIV vaccination with adenoviral vector-based nanocomplexes using mucoadhesive and DC-targeting adjuvants.Pharmaceutical research · 2014Article
- In vitro efficacy of polysaccharide-based nanoparticles containing disease-modifying antirheumatic drugs.Pharmaceutical research · 2014Article
- Strategies for intranasal delivery of vaccines.Drug delivery and translational research · 2013Article
- Surfactants modify the release from tablets made of hydrophobically modified poly (acrylic acid).Results in pharma sciences · 2013Article
- Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review.International journal of nanomedicine · 2012Review
- Nasal route and drug delivery systems.Pharmacy world & science : PWS · 2004Review
- The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers.Pharmaceutical research · 2004Article
- Large porous particle impingement on lung epithelial cell monolayers--toward improved particle characterization in the lung.Pharmaceutical research · 2003Article
- Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell cultures.AAPS pharmSci · 2002Article
- Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3).British journal of pharmacology · 2001Article
- Bioadhesion: new possibilities for drug administration?Clinical pharmacokinetics · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNasal delivery of protein therapeutics can be compromised by the brief residence time at this mucosal surface. Some bioadhesive polymers have been suggested to extend residence time and improve protein uptake across the nasal mucosa. We examined several potential polymer platforms for their in vitro protein release, relative bioadhesive properties and induction of cytokine release from respiratory epithelium.
methodsStarch, alginate, chitosan or Carbopol microparticles, containing the test protein bovine serum albumin (BSA), were prepared by spray-drying and characterized by laser diffraction and scanning electron microscopy. An open-membrane system was used to determine protein release profiles and confluent, polarized Calu-3 cell sheets were used to evaluate relative bioadhesion, enhancement of protein transport and induction of cytokine release in vitro.
resultsAll spray-dried microparticles averaged 2-4 microm in diameter. Loaded BSA was not covalently aggregated or degraded. Starch and alginate microparticles released protein more rapidly but were less adhesive to polarized Calu-3 cells than chitosan and Carbopol microparticles. Protein transport across polarized Calu-3 cells was enhanced from Carbopol gels and chitosan microparticles. A mixture of chitosan microparticles with lysophosphatidylcholine increased protein transport further. Microparticles prepared from either chitosan or starch microparticles, applied apically, induced the basolateral release of IL-6 and IL-8 from polarized Calu-3 cells. Release of other cytokines, such as IL-1beta, TNF-alpha, GM-CSF and TGF-beta, were not affected by an apical exposure to polymer formulations.
conclusionsWe have described two systems for the in vitro assessment of potential nasal platforms for protein delivery. Based upon these assessments, Carbopol gels and chitosan microparticles provided the most desirable characteristics for protein therapeutic and protein antigen delivery, respectively, of the formulations examined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.